4-(4-溴苯氧基)苯甲酸甲酯 | 21120-75-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-溴苯氧基)苯甲酸甲酯
• 英文名称: methyl 4-(4-bromophenoxy)benzoate
• CAS: 21120-75-2
• 化学式: C₁₄H₁₁BrO₃
• 分子量: 307.144
• InChiKey: GVUFCGJTPGPJRO-UHFFFAOYSA-N

物化性质

• 熔点：
  93～95℃

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(4-溴苯氧基)苯甲酸甲酯 在 copper(l) iodide 、 (PPh)3PdCl₂ 、 potassium carbonate 、 二异丙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 methyl 4-(4-ethynylphenoxy)benzoate
  参考文献：
  名称：

  Structure–activity study of retinoid agonists bearing substituted dicarba-closo-dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei

  摘要：

  We have investigated the structure-activity relationships of the potent retinoid agonist, 4-[4-(2-propyl-1,2-dicarba-closo-dodecaboran-1-yl)phenylamino]benzoic acid (BR403), which we have previously reported. Substitution of a methyl group on the aromatic nucleus or a methyl group on the nitrogen atom, or replacement of the amino group with ether, methylene, carboxyl or 1,1-ethylene greatly decreased the activity. The relatively planar conformation at the phenyl-N-phenyl moiety seems to play a critical role in the appearance of the biological activity. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00204-9
• 作为产物：
  描述：

  potassium phenolate 在 四氯化碳 、 basic copper carbonate powder 、 溴 、 铜 、 苯酚 作用下， 生成 4-(4-溴苯氧基)苯甲酸甲酯
  参考文献：
  名称：

  Bone turnover in hyperthyroidism before and after thyrostatic management

  摘要：

  Hyperthyroidism is associated with enhanced osteoblastic and osteoclastic activity, and patients frequently have low bone mineral density and high bone turnover. The aim of this study was to examine the bone formation and resorption markers trend in 12 female patients, before and after normalization of thyroid activity. The following measurements were made at baseline and 1 and 6 months after hormone normalization induced by methimazole treatment: total alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), collagen type C-terminal propeptide (PICP), osteocalcin (BGP), telopeptide (ICTP), urinary-hydroxyproline/urinary creatinine (uOHP/uCreat), urinary calcium/urinary creatinine (uCa/uCreat) and deoxypyridinoline crosslinks (D-Pyr). Compared with controls, all of these parameters were significantly increased (ALP p=0.014; BALP p=0.0001; PICP p=0.013; BGP p=0.009; ICTP p=0.0001; uOHP/uCreat p=0.002; uCa/uCreat p=0.044; crosslinks p=0.0001). After treatment the values of ALP, BALP and PICP in hyperthyroid patients showed an initial slight increase and then a significant downwards trend (ALP p=0.008, BAP p=0.001, PICP p=0.026). furthermore, resorption markers showed a significant decrease (uOHP/uCreat p<0.005 and D-Pyr p<0.008). As regards lumbar BMD patients, measurements were significantly reduced in comparison with the control group (p=0.005). Six months after serum thyroid hormones level normalization, we observed a significant increase (p=0.014 vs baseline). Both neoformation and resorption markers are useful to assess pathological bone turnover and bone involvement in hyperthyroidism. They could also be employed to monitor the effect of antithyroid treatment on bone and to indicate if bone antiresorption therapy should be considered. (C) 2000, Editrice Kurtis.

  DOI：

  10.1007/bf03345061

文献信息

• General Synthesis of Retinoids and Arotinoids via Palladium-Catalyzed Cross-Coupling of Boronic Acids with Electrophiles
  作者：Alicia Torrado、Susana López、Rosana Alvarez、Angel R. de Lera

  DOI：10.1055/s-1995-3905

  日期：1995.3

  A novel approach to the synthesis of retinoids and arotinoids (including heterocyclic analogs) is described which is based on the thallium-accelerated palladium-catalyzed cross-coupling of boronic acids with a variety of electrophiles (the Suzuki reaction).

  本文介绍了一种制备类视黄醇和阿洛视黄醇（包括杂环类似物）的新方法，该方法基于铊促进的钯催化下硼酸与多种亲电试剂的交叉偶联合成反应（Suzuki反应）。
• 二氢嘧啶类化合物及其在药物中的应用
  申请人：广东东阳光药业有限公司

  公开号：CN109111451B

  公开（公告）日：2020-08-11

  本发明涉及一种二氢嘧啶类化合物及其作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。具体地说，本发明涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐作为药物的用途，尤其是作为治疗和预防乙型肝炎的药物的用途。
• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019001396A1

  公开（公告）日：2019-01-03

  Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.

  本文提供了一种二氢嘧啶化合物及其药物应用，特别是用于治疗和预防HBV疾病的应用。具体来说，本文提供了具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐，其中化学式的变量如规范中定义。本文还提供了将具有化学式（I）或（Ia）的化合物，或其对映体、异构体、互变异构体、水合物、溶剂合物或其药用可接受的盐用作药物的用途，特别是用于治疗和预防HBV疾病。
• DICARBA-closo-DODECABORANE DERIVATIVES
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1145718A1

  公开（公告）日：2001-10-17

  A medicament comprising as an active ingredient a compound or a physiologically acceptable salt thereof represented by general formula (I): wherein R1 represents a dicarba-closo-dodecaboran-yl which may be substituted with a lower alkyl group, a lower alkenyl group, carboxyl group or the like; R2 represents carboxyl group, a lower alkoxycarbonyl group, or hydroxyl group; and X represents a single bond or a linking group such as -CO-Y1- wherein Y1 represents oxygen or -N(R3)-wherein R3 represents hydrogen or a lower alkyl.

  一种药物，其活性成分为由通式（I）表示的化合物或其生理上可接受的盐，其中R1代表可用较低的烷基基团、较低的烯基基团、羧基等取代的二碳杂十二硼基；R2代表羧基、较低的烷氧羰基，或羟基；X代表单键或类似-CO-Y1-的连接基团，其中Y1代表氧或-N（R3）-，其中R3代表氢或较低的烷基。
• [EN] COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT, DE DÉPISTAGE, ET D'IDENTIFICATION DE COMPOSÉS DESTINÉS À TRAITER LES MALADIES PROVOQUÉES PAR DES PARASITES APICOMPLEXES
  申请人：MCLEOD RIMA

  公开号：WO2017112678A1

  公开（公告）日：2017-06-29

  Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to teat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

  本公开的内容包括：用于治疗顶复合体寄生虫相关疾病的新化合物，其使用方法；休眠寄生虫表型的细胞系和非人类动物模型，以及用于识别新药物治疗顶复合体寄生虫相关疾病的方法，以及用于识别由寄生虫引起的疾病及其对治疗的反应的生物标志物。